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Abstract
Introduction: Multiple myeloma (MM) is the leading indication for autologous stem cell transplantation (ASCT), with over 
12,000 transplants per year in Europe. Due to low toxicity, an entirely outpatient procedure or an early discharge after 
ASCT can be considered as alternatives to inpatient transplantation. Thus, we launched an Early Discharge Program 
(EDP) for patients qualified for ASCT due to MM who were under 60 years of age, without significant comorbidities, who 
had a caregiver available 24/7, and who lived within a 60-minute drive of our hospital.
Material and methods: Patients spent 72 hours in the hospital being administered melphalan 200 mg/m2 intravenous 
followed by an infusion of hematopoietic stem cells. They were eventually discharged and remained under outpatient 
care. The program was launched in September 2019 and was temporarily halted due to the coronavirus disease 19 
(COVID-19) pandemic in early 2020. Five patients were enrolled to the EDP.
Results: Non-hematological toxicity was mild and manageable in an outpatient setting. Only one patient was readmitted 
due to exacerbation of ulcerative colitis that was probably not related to ASCT. We observed neither infections nor bleeding. 
Due to hematological toxicity, three of the five patients received platelet transfusion on the 6th day after ASCT as outpa-
tients. No packed erythrocytes were transfused. The EDP demonstrated lower costs compared to an inpatient approach.
Conclusions: We believe that early discharge, which is an intermediate step to full at-home transplantation due to pa-
tients’ wellbeing, reduction of infections caused by resistant microorganisms, and costs, will eventually replace a full 
inpatient procedure for a significant population of patients suffering from multiple myeloma and indeed other diseases.
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Introduction
Despite the widespread development of new drugs for 
the treatment of multiple myeloma (MM), high-dose che-
motherapy followed by autologous stem cell transplantation 
(ASCT) remains the standard of care for all eligible patients 
[1, 2]. Currently MM is the leading indication for ASCT, 
with over 12,000 transplants per year in Europe [3]. The 
standard conditioning for ASCT is melphalan (200 mg/m2) 
plus infusion of peripheral blood stem cells 24 hours later. 
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Hospital stays in a transplant unit usually last up to 20 days, 
due to logistical issues and the probability of complications 
before hematopoiesis recovery.
However, given low transplant-related mortality (<3%), 
and low non-hematological toxicity, an outpatient approach 
should be considered as an option. This procedure could be 
performed entirely as an outpatient, with patients  sleeping 
at home and then attending scheduled outpatient visits [4].
An intermediate variant between these two approaches 
involves early discharge after stem cell infusion (Figure 1) 
where the patient stays in hospital for a very limited period 
of time [5]. Outpatient transplantation is an attractive op-
tion due to the enhanced ease of living, the lower risk of 
infections caused by resistant bacteria, and the increased 
access to high-risk transplantations that need to be per-
formed fully in the hospital. An additional argument is the 
significant cost reduction. Thus, we introduced a pilot Ear-
ly Discharge Program (EDP) for patients with MM in order 
to pave the way towards fully outpatient transplantations.
Material and methods
We included in the EDP patients under 60 years of age, 
in good general condition [ECOG (Eastern Cooperative 
Oncology Group) 0–1], without significant comorbidities 
[HCT-CI (Hematopoietic Cell Transplantation — Specific 
Comorbidity Index) <2], with at least a very good partial 
response (VGPR), who had had their first transplantation 
[6]. An additional condition was: the presence of a caregiver 
(i.e. a family member/friend who takes care of the patient at 
home and in case of emergency assists with transportation 
to hospital), and a distance from home to the transplant 
center of less than 60 minutes’ driving. Participation in the 
EDP was entirely voluntary and was widely discussed with 
the patient and his or her family before enrolment.
The timeline of the EDP is depicted in Figure 2. Prefe-
rably patients had a vascular port implanted on an outpa-
tient basis. If this was not performed, during the first day 
a central venous catheter (CVC) was attached. On the se-
cond day of hospitalization, melphalan was administered 
at the standard dose of 200 mg/m2 intravenou (i.v.) 24 ho-
urs afterwards, stem cells were infused. On the day after 
transplantation (day +1), the patient was discharged. The 
patient was provided with phone contact to qualified medi-
cal staff available 24/7 (nurse and physician). For the stay 
at home, the patient and the caregiver were given a deta-
iled schedule of care as well as lifestyle guidelines (e.g. diet, 
personal hygiene and social behavior). The schedule consi-
sted of recommended drugs and monitoring of vital para-
meters (i.e. blood pressure, temperature, heart rate, daily 
urine collection). The supportive treatment included antie-
metic (ondansetron 16 mg suppository rectally in case of 
nausea), antifungal (fluconazole 200 mg bid) and antiviral 
(acyclovir 800 mg bid) drugs. Starting from day +3, filgrastim 
was administered until the reconstitution of hematopoiesis 
(once a day at a dose depending on weight: 30 million or 
48 million IU subcutaneously). The patient was told that, in 
the event of alarming symptoms such as fever or bleeding, 
he or she should contact the transplant center immediately.
After discharge, a certified and experienced transplant 
nurse twice a day (at 9 am and 6 pm) contacted the pa-
tient/caregiver. During the conversation, the patient was 
asked to provide the following data: temperature, blood 
pressure, heart rate, amount of fluid drunk and volume of 
daily urine collection. In addition, the presence of other 
symptoms (weakness, nausea, vomiting, diarrhea, diathe-
sis, etc.) was recorded on an observation sheet and shown 
to the physician/nurse during a control visit.
Scheduled control visits in the transplant center took 
place on the appointed dates on day +6 and day +10. Du-
ring the visit, physical examination and standard labora-
tory tests were performed to assess any need for blood 
product transfusions, symptoms of infection, electrolyte 
abnormalities, etc. If necessary, the patient was hospitali-
zed or transfused on an outpatient basis.
Results
We performed a transplantation in our EDP in five patients 
(three women, two men) with a median age of 58. For all pa-
tients, this was their first transplantation. All patients were 
in VGPR after a median of four VTD induction chemotherapy 
cycles. Patients had HCT-CI 0 with one exception — one 
patient had G1 ulcerative colitis in their medical history 
Figure 1. Different approaches to autologous stem cell transplan-
tation (ASCT) in patients with multiple myeloma; CVC — central ve-
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without any ongoing symptoms and treatment. The patients 
were not colonized with multi-drug resistant (MDR) bacteria. 
The program was launched in September 2019 and was 
temporarily halted in March 2020 due to the coronavirus 
disease 19 (COVID-19) pandemic.
One patient refused vascular port implantation due to 
wishing to retain the possibility of recreational swimming. 
The other four had a vascular port implanted. All patients 
received standard conditioning (melphalan 200 mg/m2 i.v.) 
on the second day after admission. The transplantation 
was performed on the following day at least 24 hours after 
melphalan infusion. The median number of infused CD34+ 
cells was 4.2 ×106/kg. All patients were discharged on the 
day after transplantation, as planned. Patients were under 
the continuous control of an experienced transplant nurse 
(a phone call twice a day) and followed the guidelines prepared 
for each day by the transplant team. Patients were routine-
ly admitted as originally scheduled on day +6 and day +10.
All patients survived, and all had reconstitution of he-
matopoiesis. The median time of granulopoiesis reconstitu-
tion was 12 days (9–13). 3/5 patients had platelets trans-
fusions: median nadir of platelets was 16 G/l, and median 
number of platelet transfusions was 1 (0–2). There was no 
necessity for packed erythrocytes transfusion. One patient 
was readmitted on day +7 because of diarrhea G3 which 
was likely due to exacerbation of ulcerative colitis. There 
were no neutropenic fevers observed. Vomiting/nausea 
G2 was reported in 3/5 patients. Mucositis G2 was observed 
in one patient but this neither affected nutrition nor caused 
weight loss. On day +100 follow up, 3/5 had achieved com-
plete response (CR) and 2/5 remained in VGPR.
The cost of the procedures and hospitalization in the 
EDP was 16,785 PLN on average (including control visits 
and transfusions), while for standard procedures it would 
have been 41,747 PLN (calculated for five random patients 
treated at the same time using a fully inpatient approach).
Discussion
Bone marrow transplantation in MM remains the standard 
of care and should be performed in every patient who is 
eligible [7]. The number of transplantations in multiple 
myeloma is in fact increasing, but due to the limited access 
to transplant beds in Poland, only 29% of MM patients 
undergo ASCT, which is much lower than in other Euro-
pean Union (EU) countries [8]. Thus, optimizing existing 
resources would increase the effectiveness of myeloma 
treatment. The demand for transplantation beds is rising 
not only because of the recommendations of tandem 
transplantations in MM, but also due to broadening indica-
tions for transplantations in diseases other than MM, the 
increasing availability of donors following the introduction 
of haploidentical procedures, and the recently launched 
chimeric antigen receptor T (CAR-T).
An outpatient approach (full or partial) can be an attrac-
tive option because it offers enhanced ease of living, shorter 
inpatient stay, a lower risk of infection, and a lower cost of 
procedures. This type of transplantation has been effectively 
performed in several transplant centers worldwide for several 
years [9, 10]. An outpatient transplant is proven to be safe 
without any impact on progression-free survival or overall 
survival (treatment-related mortality does not exceed 1%), 
and it does not impact on reconstitution, as shown in ran-
domized studies or large retrospective observations [9, 11]. 
We have not to date observed any impact of the EDP on MM 
in terms of progression, survival or disease status.
An outpatient approach has been related to a better 
quality of life, mostly in terms of emotional wellbeing, so-
mething which is confirmed in our observation [12].
The toxicity of outpatient HSCT remains low, as seen in 
our pilot program. The major challenge remains readmis-
sion, which varies from 10% to 20% in patients undergoing 
ASCT due to MM [10]. A higher risk of re-hospitalization is 
related to the status of renal function (creatinine >2 vs. 
<2 mg/dL) and the timing of transplantation (frontline vs 
delayed), and thus we excluded such patients. A higher 
risk is also related to mucositis which is relatively difficult 
to predict [10]. The main reason for readmission is neutro-
penic fever which is observed in 14–60% of patients [13]. 
This fever is not an automatic reason for readmission, and 
in an outpatient program an attempt to treat infection on 
an outpatient basis remains an option. Fever is an indica-
tion for admission in patients who are unstable hemody-
namically and colonized by MDR bacteria, and thus such 
colonization should be considered as a contraindication for 
an outpatient approach. The only readmission in our small 
group was exacerbation of ulcerative colitis, and this was 
probably not directly related to ASCT.
The outpatient procedure shows a cost reduction of 
up to 60%. We observed a similar range in our pilot EDP, 
and this is a substantial advantage over a fully inpatient 
procedure [9].
Figure 2. Timeline of Early Discharge Program; D — number of days starting from day of transplantation (day 0); i.v. — intravenous; 
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A fully outpatient transplant procedure is possible only 
with extensive logistical facilities, including isolated clinics, 
dedicated teams, and an appropriate financing system, 
which are not possible in Poland under the current con-
ditions. For this reason, taking into account the benefits 
of longer stays at home (outside the hospital), in consul-
tation with the Greater Poland Branch of the National He-
alth Fund, we started a pilot EDP program for patients with 
MM. Early discharge was possible due to the optimization 
of peri-transplant procedures and with the involvement of 
the transplant team.
Conclusions
Outpatient transplantations in MM, as we have shown in our 
pilot program, are safe and achievable to implement even 
given the current system of financing of transplantations.
The end of the COVID-19 pandemic will allow us to re-
new our EDP, which we hope will confirm good tolerability 
and safety of an outpatient approach in a larger group of 
patients and eventually promote this form of transplanta-
tion nationwide. Due to several advantages such as pa-
tient wellbeing, reduced infections caused by resistant 
microorganisms, and lower costs, an outpatient approach 
is recommended by international societies such as the 
European Society for Blood and Marrow Transplantation 
(EBMT) for malignancies other than MM and also for allo-
geneic transplantations.
Outpatient transplantation should be considered espe-
cially for younger patients with a low risk of procedure, in 
good general condition, with normal kidney function, not 
colonized by MDR bacteria, who live close to the transplant 
center, and who have a caregiver available.
We believe that our EDP, through the development of 
outpatient logistics, will evolve to become fully at-home tre-
atment for a significant population of patients [6].
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